Note: This document contains side effect information about valbenazine. Some dosage forms listed on this page may not apply to the brand name Ingrezza.

Summary

Common side effects of Ingrezza include: drowsiness, fatigue, and sedated state. Continue reading for a comprehensive list of adverse effects.

Applies to valbenazine: oral capsules.

Side effects include:

Adverse effects occurring in ≥2% of patients receiving valbenazine (the active ingredient contained in Ingrezza) in short-term tardive dyskinesia clinical trials and at a higher frequency than reported with placebo include somnolence (including fatigue and sedation), anticholinergic effects (including dry mouth, constipation, attention disturbance, blurred vision, and urinary retention), balance disorders (including falls, gait disturbances, and dizziness), headache, akathisia/restlessness, vomiting, nausea, and arthralgia.

For Healthcare Professionals

Applies to valbenazine: oral capsule.

General

-The most common adverse reaction (5% or more and twice the rate of placebo) was somnolence.

-A total of 3% of patients discontinued treatment because of adverse reactions.^[Ref]

Nervous system

Very common (10% or more): Somnolence/fatigue/sedation (10.9%)

Common (1% to 10%): Anticholinergic effects (dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders/fall/gait disturbance/dizziness, headache, akathisia/restlessness, drooling, dyskinesia,

non-akathisia extrapyramidal symptoms^[Ref]

Gastrointestinal

Common (1% to 10%): Vomiting, nausea^[Ref]

Hepatic

Common (1% to 10%): Increased alkaline phosphatase and bilirubin^[Ref]

Metabolic

Common (1% to 10%): Increased blood glucose, increased weight, increased prolactin^[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia^[Ref]

Psychiatric

Common (1% to 10%): Anxiety, insomnia^[Ref]

Respiratory

Common (1% to 10%): Respiratory infections^[Ref]